Genmab — Oktober 2017
-
Med nuværende problemer, som er vanskelige at se en løsning på vil CAR-T aldrig have en chance i firstline, når alternativet er en sikker behandling. Tænk på hvor enkelt en sc-dara og rev pille vil være first line. I denne behandling og måske også med Velcade vil en pæn del af patienterne også blive helbredt.
-
-
han er ellers kendt for at have tjent et par $ ved sine investeringer http://investors-strategy.com/25-rules-on-investing-and-success?campaign=846454016&adgroup=44720392073&targetid=kwd-296201264040&network=d&creative=198736711349&placement=www.streetinsider.com&target=&adposition=none&keyword=dow jones futures&matchtype=&locationofinterest=&physicallocation=1005142&device=c&devicemodel=&gclid=CIaZ_PCJm9cCFXEW0wodTfMEBw
-
SEB sænker målkurs på Genmab til 1280 fra 1430. SEB h
ar stadig en hold anbefaling.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind